Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Neuronetics ( (STIM) ) has issued an update.
On July 15, 2025, Neuronetics appointed Steven Pfanstiel as Executive Vice President, Chief Financial Officer, and Treasurer, succeeding Steve Furlong, who will retire in March 2026. Pfanstiel brings extensive experience from his previous roles in the healthcare industry, notably at Marinus Pharmaceuticals and LifeScan. His appointment is part of Neuronetics’ strategic vision to expand access to mental health treatments and achieve sustainable growth. The company also reaffirmed its financial guidance for the second quarter and full year 2025, highlighting its ongoing integration of Greenbrook operations and its path to achieving positive cash flow in the third quarter of 2025.
The most recent analyst rating on (STIM) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Neuronetics stock, see the STIM Stock Forecast page.
Spark’s Take on STIM Stock
According to Spark, TipRanks’ AI Analyst, STIM is a Neutral.
Neuronetics’ overall stock score is primarily hindered by its weak financial performance and poor valuation metrics, which are significant risks. The technical analysis further reflects a bearish sentiment. However, the earnings call provided some optimism with growth initiatives and strategic goals. Corporate events are positive but do not weigh heavily due to the exclusion of this component in the final score.
To see Spark’s full report on STIM stock, click here.
More about Neuronetics
Neuronetics, Inc. is a vertically integrated, commercial stage medical technology and healthcare company focused on transforming the lives of patients with neurohealth therapies. The company offers NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for neurohealth conditions, and operates Greenbrook TMS treatment centers across the United States, providing treatments for major depressive disorder (MDD) and other mental health disorders.
Average Trading Volume: 804,943
Technical Sentiment Signal: Buy
Current Market Cap: $236M
For a thorough assessment of STIM stock, go to TipRanks’ Stock Analysis page.